Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805033 | 0.78 | ELANE (0.42) | ELANECTSGPRTN3PTGS2GAA | |
| SCHEMBL29059754 | 0.73 | MAOA (0.43) | ELANECTSGPRTN3ALDH1A1MAOA | |
| SCHEMBL4701574 | 0.70 | MAOA (0.33) | ELANEGAAL3MBTL1KMT2AMAOA | |
| SCHEMBL14159710 | 0.70 | TSHR (0.43) | ELANECTSGPRTN3PTGS2GAA | |
| SCHEMBL1680374 | 0.70 | ELANE (0.40) | ELANECTSGPRTN3ALDH1A1MAOA | |
| SCHEMBL16174713 | 0.69 | ELANE (0.44) | ELANECTSGPRTN3PTGS2GAA | |
| SCHEMBL8704294 | 0.68 | MAOA (0.43) | ELANEGAAMAOAMAOB | |
| SCHEMBL16174913 | 0.68 | ELANE (0.51) | ELANECTSGPRTN3PTGS2GAA | |
| SCHEMBL6810670 | 0.68 | ELANE (0.43) | ELANECTSGPRTN3GAAL3MBTL1 | |
| SCHEMBL16174950 | 0.68 | ELANE (0.47) | ELANECTSGPRTN3L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383642-B2 | Spiropiperidine compounds | ELI LILLY AND COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110092531-A1 | Novel Spiropiperidine Compounds | ELI LILLY AND COMPANY (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092531-A1 | Novel Spiropiperidine Compounds | REN, SLC5A1, SLC5A2 | ELANE 3939/4885CTSG 3715/4885PRTN3 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.